natgillin/translations-raw huggingface dataset:
Therefore, whilst it was concluded that the claim ‘to significantly reduce the occurrence of infection with Leishmania infantum for up to 8 months due to repellent (anti-feeding) action of the product on sand flies' should not be included in the SPC, an amended indication, which accurately reflects the data provided, ‘reduction of the risk of infection with Leishmania infantum via transmission by sand flies for up to 8 months' was considered acceptable.
Kuigi järeldati, et soovitavat näidustust „patogeeni Leishmania infantum infektsiooni esinemissageduse oluline vähendamine kuni 8 kuu jooksul ravimi tõrjuva (moskiitode toitumist takistava) toime tõttu moskiitode suhtes“ ei saa lisada ravimi omaduste kokkuvõttesse, peeti aktsepteeritavaks esitatud andmeid täpselt kajastavat muudetud näidustust: „moskiitodega ülekantava patogeeni Leishmania infantum infektsiooni riski vähendamine kuni 8 kuu jooksul“
Regarding the data requirement for the demonstration of repellent (anti-feeding) efficacy against P. perniciosus, the UK did not accept that the laboratory data submitted by the MAH for the product justify the inclusion of an indication against the sand fly vector.
Arvestades nõuet tõendada andmetega moskiitode P. perniciosus vastase tõrjuvat (moskiitode toitumist takistavat) toimet, ei aktsepteerinud Ühendkuningriik müügiloa hoidja ravimi kohta esitatud laboriandmeid, mis põhjendaksid moskiitovektori vastase näidustuse lisamist.
Regarding the results of the three field studies presented by the MAH, all three studies were able to demonstrate that use of Seresto led to a significant reduction in the occurrence of infection with L. infantum over a sustained period (between 7 and 8 months), with overall mean efficacies of the collar in preventing leishmaniosis of 93.4% in the first field study, 100% in the second field study, and 88.3% in the third field study as evaluated by the incidence density rate.
Müügiloa hoidja esitatud kolme väliuuringu tulemuste järgi tõendati kõigis kolmes uuringus, et Seresto kasutamine vähendas pika aja jooksul (7-8 kuud) oluliselt patogeeniga L. infantum infektsiooni esinemissagedust, kusjuures ravimkaelarihma efektiivsus leišmanioosi ennetamisel esinemissageduse järgi hinnates esimeses väliuuringus 93,4%, teises 100% ja kolmandas 88,3%.
Although a significant reduction in the incidence of Leishmania infantum in dogs has been demonstrated, the product has shown variable repellent (anti-feeding) and insecticidal efficacy against the sand fly Phlebotomus perniciosus.
Kuigi on demonsteeritud märkimisväärset Leishmania infantum juhtude vähenemist koertel, on ravim näidanud erinevat peletavat (toitumisvastast) ja insektitsiidset toimet moskiito Phlebotomus perniciosus vastu.
The anti-feeding efficacy demonstrated for Seresto is, therefore, considered insufficient for the inclusion of a direct repellent claim against P. perniciosus.
Seega peetakse Seresto korral moskiitode toitumist takistavat tõendatud toimet ebapiisavaks, et ravimiteabesse lisada otsene väide moskiito P. perniciosus vastase tõrjuva toime kohta.
A claim for ‘reduction of the risk of infection with Leishmania infantum via transmission by sand flies for up to 8 months' has been adequately demonstrated.
Väide „moskiitode ülekantava patogeeni Leishmania infantum infektsiooni riski vähendamine kuni 8 kuu jooksul“ on adekvaatselt tõendatud.
Efficacy evaluation was based on the comparison of the percentage of animals infected by L. infantum in the treated and untreated groups at the end of the study.
Efektiivsuse hindamine põhines patogeeni L. infantum infektsiooniga loomade protsendi võrdlemisel ravitud ja ravimata loomade rühmades uuringu lõpus.
The third field study was a double positive and negative controlled, partially blinded, randomised multicentre field study.
Kolmas väliuuring oli positiivse ja negatiivse topeltkontrolliga randomiseeritud mitmekeskuseline väliuuring, milles kasutati osaliselt pimemenetlust.
Efficacy evaluation for Seresto was based on the comparison of the percentage of animals infected by L. infantum in the Seresto treated and untreated groups at the end of the study.
Seresto efektiivsuse hindamine põhines patogeeni L. infantum infektsiooniga loomade protsendi võrdlemisel Serestoga ravitud ja ravimata loomade rühmades uuringu lõpus.
• the CVMP considered that the efficacy of Seresto, and its associated name Foresto, relating to the transmission or occurrence of Leishmania infantum in dogs has been satisfactorily demonstrated in the field studies provided;
• veterinaarravimite komitee oli arvamusel, et Seresto ja sarnase nimetuse Foresto efektiivsus seoses patogeeni Leishmania infantum ülekande või esinemissageduse vähendamisega koertel on esitatud väliuuringutes rahuldavalt tõendatud;
For the protective claim sought, demonstration of an anti-feeding activity for Seresto against sand flies was considered a prerequisite by the CVMP as the active substances in the Seresto collar, imidacloprid and flumethrin, have no known efficacy against Leishmania and therefore, any preventative efficacy against leishmaniosis is purely a result of efficacy against the sand fly.
Taotletava kaitsva väite aspektist pidas veterinaarravimite komitee eeltingimuseks, et tõendatud on Seresto toime moskiitode toitumise vastu, sest Seresto ravimkaelarihma toimeainetel imidaklopriidil ja flumetriinil puudub teadaolev Leishmania-vastane toime ja seega põhineb leišmanioosi ennetav efektiivsus ainult moskiitovastasel efektiivsusel.
The three field studies provided demonstrated that, depending on the infection pressure by sand flies, use of Seresto reduced the risk of infection with L. infantum by 88.3-100%.
Esitatud kolmes väliuuringus tõendati, et sõltuvalt moskiitode infektsioonisurvest vähendas Seresto kasutamine patogeeni L. infantum riski 88,3…100% võtta.
However, the consistently low ratios of fed to unfed females seen in the laboratory studies are considered supportive of the field studies results.
Arvestades laboriuuringutes pidevalt täheldatud toitunud ja toitumata emaste moskiitode väikest suhet, peetakse neid tulemusi väliuuringuid toetavateks.
The indication proposed by the RMS, and agreed by the majority of the concerned Member States (CMSs), at the referral stage was “To significantly reduce the occurrence of infection with Leishmania infantum for up to 8 months due to repellent (anti-feeding) action of the product on sand flies.”
Viiteliikmesriigi pakutud näidustus, millega nõustus enamik asjaomaseid liikmesriike, oli esildise staadiumis järgmine: „Patogeeni Leishmania infantum infektsiooni esinemissageduse oluline vähendamine kuni 8 kuu jooksul ravimi moskiitosid tõrjuva (moskiitode toitumist takistava) toime tõttu.“
Conclusion on the benefit-risk balance
Järeldus kasulikkuse ja riski tasakaalu kohta
The MAH also provided an alternative analysis of the laboratory data from all 3 studies using ratios of fed to unfed sand flies for efficacy calculation.
Müügiloa hoidja esitas kõigi kolme uuringu laboriandmete alternatiivse analüüsi, milles arvutati efektiivsus toitunud ja toitumata moskiitode arvu suhte järgi.
The efficacy threshold of 80-100% (preferably 90%) as recommended in the guideline Demonstration of Efficacy of Ectoparasiticides (7AE17a)1 was not met at sufficient time points.
Nõutud ajapunktides ei olnud saavutatud ektoparasiitide vastase efektiivsuse tõendamise suunises „Demonstration of Efficacy of Ectoparsiticides“ (7AE17a)1 soovitatud efektiivsusläve 80…100% (eelistatavalt 90%).
During the course of the procedure, the indication was amended by the reference Member State (RMS) who stated that ‘the demonstration of efficacy of the product against the sand flies over the whole season is a prerequisite for the claimed indirect prevention of transmission of L. infantum.
Menetluse käigus muutis viiteliikmesriik näidustust, märkides, et taotletava näidustuse - patogeeni L. infantum ülekande kaudne ennetamine - eeltingimus on moskiitovastase efektiivsuse tõendamine kogu hooaja jooksul.
The first study was a negatively-controlled, randomised, multicentre field study, which was partially blinded.
Esimene uuring oli negatiivse kontrolliga randomiseeritud mitmekeskuseline väliuuring, milles osaliselt kasutati pimemenetlust.
In the case of the sand fly and L. infantum, the active substances in Seresto, imidacloprid and flumethrin, have no known efficacy against the Leishmania parasite and therefore any preventative efficacy against leishmaniosis would be purely as a result of efficacy against the sand fly.
Seresto toimeainetel imidaklopriidil ja flumetriinil puudub teadaolev toime moskiitode ja patogeeni L. infantum vastu, mistõttu mis tahes leišmanioosivastane ennetav efektiivsus põhineb ainult moskiitovastasel efektiivsusel.
Reduction of the risk of infection with Leishmania infantum via transmission by sand flies for up to 8 months.
Moskiitode poolt Leishmania infantum'i ülekandumise riski vähendamine kuni 8 kuu jooksul.
A total of 224 dogs, of several breeds and aged between 7 and 77 weeks, were enrolled, blocked by pens and pens were randomised to one of four groups.
Uuringusse kaasati kokku 224 eri tõugudest koera vanuses 7-77 kuud, kes olid eraldatud aedikutesse.
• the CVMP considered that the consistently low ratios of fed to unfed female sand flies seen in the laboratory studies are regarded supportive of the field study results;
• veterinaarravimite komitee oli arvamusel, et laboriuuringutes pidevalt täheldatud toitunud ja toitumata emaste moskiitode väike suhe toetab väliuuringute tulemusi,
Bayer Healthcare, 220 Avenue de la Recherche 59120, Loos, France
Prantsusmaa Bayer Healthcare, 220 Avenue de la
Three field studies, performed in situations with high infection pressure for leishmaniosis, demonstrated that the occurrence of new cases of L. infantum is significantly reduced in dogs treated with Seresto.
Leišmanioosi suure infektsioonisurvega olukordades tehtud kolmes väliuuringus tõendati, et Serestoga ravitud koertel väheneb oluliselt patogeeni L. infantum uute juhtude esinemissagedus.
The application was submitted as a Type II variation for the addition of the new therapeutic indication ‘to significantly reduce the occurrence of infection with Leishmania infantum for up to 8 months due to repellent (anti-feeding) action of the product on sand flies'.
Taotlus esitati II tüüpi muudatusena, et lisada uus näidustus: „patogeeni Leishmania infantum infektsiooni esinemissageduse oluline vähendamine kuni 8 kuu jooksul ravimi tõrjuva (moskiitode toitumist takistava) toime tõttu moskiitode suhtes“.
Animals were defined as noninfected by Leishmania when seronegative for circulating anti-L. infantum antibodies and negative to PCR of skin tissue and bone marrow aspirate samples.
Patogeeni Leishmania infektsioonita loomad olid määratletud kui loomad, kelle veres puudusid patogeeni L. infantum vastased antikehad ning kelle nahakoe ja luuüdi aspiraadi proovide PCR-analüüsi tulemus oli negatiivne.
The marketing authorisation holder (MAH) submitted a variation application to add a new therapeutic indication: “Indirect protection against the transmission of pathogen Leishmania infantum by sand flies (Phlebotomus perniciosus) thereby reducing the risk of canine leishmaniosis for 7 to 8 months”.
Müügiloa hoidja esitas müügiloa muutmise taotluse uue näidustuse lisamiseks: „Kaudne kaitse patogeeni Leishmania infantum ülekande eest moskiitodega (Phlebotomus perniciosus), millega väheneb koerte leišmanioosi risk 7-8 kuuks.“ Taotluse toetuseks esitas müügiloa hoidja labori- ja väliuuringute tulemused.
As a result, bites by sand flies may occur, and the transmission of L. infantum cannot be completely excluded.
Seega on siiski võimalik moskiitopisted, mistõttu ei ole võimalik täielikult välistada patogeeni L. infantum ülekannet.
The second field study was a negatively-controlled, single centre, partially-blinded, clinical field study.
Teine väliuuring oli negatiivse kontrolliga ühekeskuseline kliiniline väliuuring, milles osaliselt kasutati pimemenetlust.
The MAH has provided three GCP-compliant laboratory studies, conducted in order to determine the anti-feeding and insecticidal efficacy of the test product against sand flies.
Müügiloa hoidja on esitanud kolm headele kliinilistele tavadele vastavat laboriuuringut, milles uuriti ravimi moskiitode toitumist takistavat ja moskiitovastast insektsitsiidset toimet.
Although a significant reduction in the incidence of L. infantum in dogs has been demonstrated, the product has shown variable repellent (anti-feeding) and insecticidal efficacy against the sand fly P. perniciosus.
Kuigi tõendatud on patogeeni L. infantum esinemissagedust oluliselt vähendav toime, on ravimi tõrjuv (moskiitode toitumist ennetav) ja insektitsiidne toime moskiitode P. perniciosus vastu olnud varieeruv.
12 SPECIAL WARNING(S)
NÄIDUSTUS(ED)
Repellent efficacy was assessed by comparing the number of fed female sand flies in the treated animals to the number of fed female sand flies in the untreated animals.
Tõrjuva toime efektiivsuse hindamiseks võrreldi toitunud emaste moskiitode arvu ravitud loomadel toitunud emaste moskiitode arvuga ravimata loomadel.
This is a variation application for an already-authorised product (Seresto); no further risks have been identified in the studies provided.
Esitatud uuringutes ei tuvastatud täiendavaid riske.
2 Guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats (EMA/CVMP/EWP/005/2000-Rev.2) - link skin tissue being collected on study days 0, 90, 180, 210, and 300 (i.e. in the post-treatment phase), and samples of bone marrow collected on study days 0 and D300.
2 Guideline for the testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats (EMA/CVMP/EWP/005/2000-Rev.2) - link
Foresto 4.50 g + 2.03 g, g zgardă antiparazitară pentru câini >8 kg
Foresto 4,50 g + 2,03 g, zgardă antiparazitară pentru câini >8 kg
The study duration was 300 days ± 10 days, and the treated animals wore the collar for the first 210 ± 10 days of this period.
Uuringu kestus oli 300 ± 10 päeva ja ravitud loomad kandsid ravimkaelarihma sellest perioodist esimesed 210 ± 10 päeva Loomi uuriti leišmanioosi suhtes vereja nahakoe proovidest, mis võeti uuringu päevadel 0, 90, 180, 210 ja 300 (st ravijärgses faasis), ning luuüdi proovidest, mis võeti uuringu päevadel 0 ja D300.
Strength
Recherche
In support of the efficacy of Seresto relating to the transmission or occurrence of Leishmania infantum in dogs, the MAH provided three field studies.
Müügiloa hoidja esitas kolm väliuuringut, et toetada Seresto efektiivsust seoses patogeeni Leishmania infantum ülekandega koertele ja koertel esinemisega.
4 INDICATIONS
ERIHOIATUSED
The European Commission granted a marketing authorisation valid throughout the European Union, for Zuprevo on 6 May 2011.
Euroopa Komisjon andis Zuprevo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 6. mail 2011.
Zuprevo tildipirosin
Zuprevo tildipirosiin
The medicine should not be given into a blood vessel.
Ravimit ei tohi süstida veresoonde.
In case of accidental contact, the skin should be washed immediately with soap and water, and the eyes flushed with clean water.
Juhuslikul nahale sattumisel tuleb nahka otsekohe pesta seebi ja veega ning silmi loputada puhta veega.
Zuprevo is a veterinary medicine that contains tildipirosin.
Zuprevo on veterinaarravim, mis sisaldab tildipirosiini.
This medicine is not allowed to be used in animals producing milk for human consumption.
Ravimit ei tohi kasutada loomadel, kelle piima tarvitatakse inimtoiduks.
The animal should be monitored and if signs of respiratory problems are still present after two days (pigs) or two to three days (cattle), the treatment should be switched to another antibiotic.
Loomi tuleb jälgida ja kui sigadel esineb 2 päeva ja veistel 2-3 pärast süstimist endiselt hingamisteede probleemid, tuleb üle minna muule antibiootikumravile.
Zuprevo is available as a solution for injection containing tildipirosin 40 mg/ml (for pigs) or 180 mg/ml (for cattle).
Zuprevot turustatakse süstelahusena, mis sisaldab 40 mg/ml (sigadele) või 180 mg/ml (veistele) tildipirosiini.
Zuprevo should only be used when the bacteria are sensitive to tildipirosin.
Zuprevot tohib kasutada üksnes siis, kui bakterid on tildipirosiini suhtes tundlikud.
Special caution should be taken to avoid accidental self-injection, as laboratory studies in dogs showed cardiovascular effects after intramuscular injection of high doses of tildipirosin.
Eriti hoolikalt tuleb vältida juhuslikku enesesüstimist, sest koertega korraldatud laboriuuringud näitasid tildipirosiini suurte annuste intramuskulaarse süsti järjel tekkivaid kardiovaskulaarseid nähte.
The withdrawal period for meat is nine days for pigs and 47 days for cattle.
Keeluaeg on sigadel 9 päeva ja veistel 47 päeva.
The treatment studies looked at the improvement of the signs of respiratory disease and the prevention studies looked at the absence of signs of infection (fever, respiratory or behaviour abnormalities) in animals exposed to infection.
Ravi uuringutes vaadeldi respiratoorse haiguse nähtude vähenemist ja ennetamise uuringutes nakkuse nähtude (palavik, hingamis- või käitumishäired) puudumist nakkusega kokku puutuvatel loomadel.
Other information about Zuprevo:
Muu teave Zuprevo kohta
229 pigs were treated with Zuprevo and 227 pigs were untreated controls that received saline.
229 siga raviti Zuprevoga, kontrollrühmas oli 227 siga, kellele süstiti füsioloogilist lahust.
The effectiveness of Zuprevo used for treatment and metaphylaxis of SRD in diseased pigs as well as in clinically healthy in-contact pigs was investigated in a field study in which an outbreak of SRD was confirmed with at least 30% of the pens showing clinical signs of SRD, including at least 10% of animals per pen within 1 day or 20% within 2 days or 30% within 3 days.
Zuprevo efektiivsust sigade respiratoorse haiguse ravis ja metafülaktikas nii haigestunud kui ka kliiniliselt tervetel, kuid haigete loomadega kokku puutunud sigadel uuriti väliuuringus, milles SRD olemasolu kinnitati vähemalt 30% SRD sümptomitega sigadel, sh ühe lauda kohta vähemalt 10% ühe päeva jooksul või 20% kahe päeva jooksul või 30% kolme päeva jooksul.
The CVMP concluded that the benefits of Zuprevo outweigh the risks for the approved indications and recommended that Zuprevo be given a marketing authorisation.
Veterinaarravimite komitee järeldas, et Zuprevo kasulikkus kasutamisel heakskiidetud näidustustel on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
Cattle may also experience pain at the time of injection.
Veised võivad süstimise ajal tunda valu.
This summary was last updated in February 2015.
Kokkuvõtte viimane uuendus: 02-2015.
In the field studies, the medicine was compared with other antibiotics used in these diseases (tulathromycin or florfenicol).
Väliuuringutes võrreldi ravimit teiste nimetatud haiguste ravimiseks kasutatavate antibiootikumidega (tulatromütsiin ja florfenikool).
Zuprevo is an antibiotic that belongs to the group ‘macrolides'.
Zuprevo on makroliidide rühma kuuluv antibiootikum.
The dose to use is calculated according to the animal's weight.
Kasutatav annus arvutatakse looma kehamassi alusel.
What is Zuprevo?
Mis on Zuprevo?
Zuprevo is given as a single injection, into muscle for pigs, and under the skin for cattle.
Zuprevot manustatakse ühekordse süstina sigadele lihasesse ning veistele naha alla.
The swelling can last for up to three days in pigs, and one to two weeks in cattle.
Turse võib püsida sigadel kuni 3 päeva ja veistel 1-2 nädalat.
When using the antibiotic Zuprevo, it is essential to closely follow the instructions in the package leaflet to minimise the development of antibiotic resistance.
Antibiootikumi (x) kasutamisel tuleb antibiootikumiresistentsuse arengu minimeerimiseks kindlasti hoolikalt järgida pakendi infolehe juhiseid.
The benefit/risk balance may be found in the scientific discussion module of this EPAR.
Zuprevo kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu jaotises.
medical advice should be sought immediately and the package leaflet or the label should be shown to the doctor.
Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
The withdrawal period is the time allowed after administration of the medicine before the animal can be slaughtered and the meat or milk used for human consumption.
Keeluaeg on ravimi manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha ega piima tarvitada toiduks.
Zuprevo should not be used in animals that are hypersensitive (allergic) to macrolide antibiotics or to any of the excipients.
Zuprevot ei tohi kasutada loomadel, kes on makroliidantibiootikumide või ravimi mis tahes abiainete suhtes ülitundlikud (allergilised).
It works by blocking the bacterias' ribosomes, the parts of the cell where proteins are produced, and blocking the growth of bacteria.
See blokeerib bakterite ribosoomid ehk rakuosad, kus toimub valgusüntees; ribosoomide blokeerimine pärsib bakterite kasvu.
Zuprevo is an antibiotic used in pigs to treat swine respiratory disease (SRD) associated with Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica and Haemophilus parasuis.
Zuprevo on antibiootikum, mida kasutatakse bakterite Actinobacillus pleuropneumoniae, Pasteurella multocida, Bordetella bronchiseptica ja Haemophilus parasuis põhjustatud sigade respiratoorse haiguse (SRD) raviks.
During severe outbreaks of SRD Zuprevo can also be used metaphylactically which means to treat at the same time both diseased pigs and those clincially healthy pigs in close contact with them, to prevent them from developing clinical signs and to prevent further spread of the disease.
SRD raskete puhangute ajal tohib Zuprevot kasutada ka metafülaktiliselt, st ravida samal ajal nii haigestunud kui ka kliiniliselt terveid, ent haigete loomadega kokku puutunud sigu, et ennetada neil kliinilisi sümptomeid ja haiguse edasist levikut.
What is the risk associated with Zuprevo?
Mis riskid Zuprevoga kaasnevad?
Why has Zuprevo been approved?
Miks Zuprevo heaks kiideti?
Animals treated with Zuprevo may develop a swelling at the site of the injection, especially when larger volumes are used, therefore each injection is limited to a maximum volume (5 ml in pigs and 10 ml in cattle).
Zuprevoga ravitud loomadel võib eelkõige suuremate mahtude kasutamise korral tekkida süstekoha turse, mistõttu on iga süsti suurim maht sigadel 5 ml ja veistel 10 ml.
How does Zuprevo work?
Kuidas Zuprevo toimib?
What is Zuprevo used for?
Milleks Zuprevot kasutatakse?
When used to prevent BRD, the presence of the disease in the herd should be confirmed before use.
Zuprevo kasutamisel veiste respiratoorsete haiguse ennetamiseks peab eelnevalt tuvastama haiguse olemasolu karjas.
When Zuprevo was used for treatment and metaphylaxis of SRD in diseased and clinically healthy incontact pigs approximately 86% of the healthy pigs remained free of clinical signs of disease compared with approximately 65% of pigs in the untreated control group.
Terveid sigu, kellel Zuprevo kasutamisel SRDga sigade ravis ja haigete loomadega kokku puutunud tervete loomade metafülaktikas ei tekkinud kliinilisi sümptomeid, oli ligikaudu 86% ja ravita kontrollrühmas 65%.
The studies in SRD included pigs between three and 21 weeks of age, and those in BRD included cattle between one and 24 months of age.
Sigade respiratoorse haiguse uuringud toimusid 3-21-nädalastel sigadel ja veiste respiratoorse haiguse uuringud 1-24-kuistel veistel.
What benefit has Zuprevo shown during the studies?
Milles seisneb uuringute põhjal Zuprevo kasulikkus?
Zuprevo is used in cattle to treat and prevent bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida and Histophilus somni.
Veistel kasutatakse Zuprevot bakterite Mannheimia haemolytica, Pasteurella multocida ja Histophilus somni põhjustatud veiste respiratoorse haiguse (BRD) ennetamiseks ja raviks.
Tildipirosin may cause sensitisation by skin contact.
Nahale sattumisel võib tildipirosiin põhjustada nahaärritust.